Panac

Quick links to important sections

Panac

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Panac

Quick Facts: Panac (Ampicillin/Dicloxacillin)

Property Description
Active Ingredients Ampicillin and Dicloxacillin
Form Typically Capsule or Tablet (Oral)
Pharmacological Class Antibiotic (Penicillin family)
Common Use Elimination of susceptible bacterial pathogens
Origin Semisynthetic

What Type of Medicine is Panac and What is Its Class?

Panac is a prescription-only medicine defined as a fixed-dose combination product designed for the systemic elimination of susceptible bacterial pathogens. It belongs to the high-level pharmacological class of Antibiotics (Anti-infective agents), specifically categorized as a β-Lactam antibiotic of the Penicillin family. This class of drug is recognized for its role in managing bacterial infections. This medication is supplied primarily for oral use in forms such as a capsule or tablet.

The Dual Active Ingredients: Ampicillin and Dicloxacillin

The medication's structure relies on two primary active ingredients that work together: Ampicillin and Dicloxacillin. Both are classified as semisynthetic penicillins, meaning they are chemically derived from the natural penicillin nucleus. Ampicillin is an Aminopenicillin providing necessary broad-spectrum activity, while Dicloxacillin is an Isoxazolyl penicillin known for its stability against certain bacterial enzymes. The strategic combination of these agents has been established in clinical practice for its effectiveness against mixed bacterial populations.

General Purpose and Mechanism of Action

The primary purpose of this specific combination antibacterial agent is to achieve definitive bactericidal action against invading organisms. The two components execute a synergistic action by both interfering with bacterial cell wall synthesis while simultaneously protecting the susceptible component from destruction. This mechanism is typically employed in a neutral use scenario where a bacterial infection is confirmed and resistance to standard penicillin is a concern. This dual action ensures reliable elimination of susceptible bacterial pathogens by pairing wide-ranging activity with essential protection against common bacterial defense mechanisms.

What side effects are possible with Panac?

Possible Side Effects and Safety Information

The safety profile of Panac (Ampicillin/Dicloxacillin) is defined by officially documented adverse reactions, classified by frequency and system-organ class, as found in regulatory prescribing information. The most frequently documented adverse events are typically categorized as Common.


Adverse Reaction Classification

Category Description (Regulatory Alignment)
Common Effects Gastrointestinal disturbances (such as diarrhea, nausea, and vomiting), and Dermatological reactions (including rash and pruritus).
Rare/Very Rare Effects Cholestatic hepatitis, severe blood dyscrasias (e.g., agranulocytosis), and seizures (neurotoxicity).

System-Organ Classes Affected

Adverse reactions are formally grouped by the body system involved. The primary systems documented are Gastrointestinal Disorders, Skin and Subcutaneous Tissue Disorders, Immune System Disorders, Hepatobiliary Disorders, and Nervous System Disorders.

Serious Adverse Reactions

While infrequent, official labeling explicitly documents several serious adverse reactions. These include Anaphylactic Shock, which is a severe, immediate hypersensitivity reaction, as well as Clostridioides difficile-associated Diarrhea (CDAD). Severe Hepatotoxicity, such as cholestatic hepatitis, and life-threatening Severe Cutaneous Adverse Reactions (SCARs) are also noted as rare possibilities.

Population-Specific Safety Considerations

The regulatory profile highlights specific constraints for certain populations. The drug is contraindicated in individuals with a known history of hypersensitivity to any penicillin. Patients with Renal Impairment have a documented increased risk of neurotoxic reactions, including seizures, due to potential drug accumulation. Additionally, patients with Infectious Mononucleosis are associated with a higher incidence of developing a skin rash during treatment with ampicillin-containing products.

Some effects are explicitly time-dependent; for instance, Anaphylaxis can occur rapidly, whereas Cholestatic Hepatitis may not present until during or shortly after treatment cessation.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Panac addresses specific clinical manifestations and the urgent actions required in the event of overdosage. Documented effects of overexposure primarily include gastrointestinal distress, such as nausea, vomiting, and diarrhea. More serious overdosage is linked to neurotoxic events, which are officially noted to include lethargy, confusion, twitching, and the potential for generalized seizures. This neurological risk is significantly elevated for individuals with severely impaired renal function, as the drug's delayed clearance can result in excessively high serum concentrations.

Regulatory bodies emphasize the high risk associated with two life-threatening outcomes: severe neurotoxicity and the rapid onset of a systemic hypersensitivity reaction (anaphylaxis).

Management of an overdose event requires the immediate discontinuation of the medicine. Since no specific antidote is known, the prescribed approach involves instituting symptomatic and supportive measures. The use of hemodialysis is an officially described procedure to help remove the active components from circulation, particularly in overdose scenarios complicated by renal compromise.

Immediate medical attention is required whenever an overdose is suspected. Official regulatory guidance mandates contacting emergency services immediately if the affected person has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened.

Therapeutic Uses of Panac

What Panac Treats: Main Uses and Benefits

Panac is commonly used for managing conditions that involve susceptible bacterial pathogens. This category of antibiotic is applicable within clinical settings that involve acute or disruptive symptom patterns, used across domains where additional symptomatic support is needed. It plays a role in managing symptoms related to systemic imbalance, such as persistent fever and malaise, and localized symptoms associated with inflammatory or irritative states.

The medication is relevant for managing conditions including skin and soft-tissue infections, respiratory tract infections, otitis media, and sinusitis. It is considered relevant when supportive symptom management is appropriate in scenarios where the pathogen mix may involve organisms resistant to standard penicillins. This supportive function provides symptomatic relief that helps patients cope more steadily and assists with maintaining a sense of stability during periods of heightened symptoms.


Quick Fact: Support for Acute Symptom Management

Feature Description
Symptom Focus Symptoms related to systemic imbalance (fever, malaise) and localized inflammatory states.
Condition Context Conditions presenting with acute bacterial episodes, including skin, respiratory, and ENT infections.
Main Benefit Offers symptomatic relief that helps patients cope more steadily and assists with maintaining a sense of stability.
Key Scenario Applied in addressing complex bacterial infections where resistance to standard penicillins is a factor.

Regulatory References

  1. NIH LiverTox Overview of Dicloxacillin

Eligibility and Restrictions for Use

Who Can and Cannot Use Panac?

This section summarizes the official population eligibility rules for Panac (Ampicillin/Dicloxacillin) as defined in regulatory labeling.


Contraindicated Populations

Panac is contraindicated and must not be used by certain populations according to official labeling:

  • Individuals with a known hypersensitivity to any penicillin or cephalosporin due to the risk of cross-allergenicity.
  • Patients with confirmed or suspected infectious mononucleosis.

Eligibility and Restricted Use

Population Group Regulatory Status Documentation Context
Adults and Pediatric Patients Generally Permitted Established use for susceptible bacterial infections.
Renal/Hepatic Impairment Restricted/Conditional Use Requires caution; dose adjustment may be necessary, particularly for the Ampicillin component in severe renal impairment.
Pregnancy Conditional Use (Category B) Use is permitted only when the potential benefit is determined to outweigh the unknown risk to the fetus.
Lactation Acceptable with Caution Drug levels in breast milk are low, but monitoring for infant gastrointestinal effects is advised.

Important Eligibility Limitations

The oral formulation of Panac is not recommended for patients with severe illness or clinical conditions that significantly impair oral absorption. Furthermore, use requires caution in individuals with a history of significant allergies or asthma due to a potentially increased risk of hypersensitivity reactions.

What should I know about interactions with other medicines?

The interaction profile for Panac (Ampicillin/Dicloxacillin) is defined by pharmacokinetic and pharmacodynamic constraints documented in official regulatory sources.

Interaction Classifications (High-Level)

Classification Description based on Regulatory Documents
Interaction Severity Classification Contraindicated (with Tetracycline antibiotics and Live Bacterial Vaccines); Clinically Significant / Requires Monitoring (with Oral Anticoagulants, Probenecid, Allopurinol); Efficacy-Reducing (with Hormonal Contraceptives).
Interaction-Context Constraints Administration requires a fasting state relative to meals to optimize Dicloxacillin absorption; co-administration with Warfarin requires specific INR monitoring procedures.

Official Interaction Statements

  • Probenecid blocks the renal tubular secretion of the penicillin components, resulting in increased and prolonged plasma concentrations of both Ampicillin and Dicloxacillin.
  • Dicloxacillin is documented as an inducer of specific CYP450 enzymes (CYP2C9, CYP2C19, CYP3A4), which may lead to reduced plasma concentrations of co-administered medicines that are substrates for these enzymes.
  • Oral Anticoagulants (e.g., Warfarin) combined with Dicloxacillin are officially associated with a risk of altered International Normalized Ratio (INR), requiring mandatory monitoring.
  • Tetracycline antibiotics are officially restricted due to the potential for therapeutic antagonism against the bactericidal activity of the penicillins.
  • The Dicloxacillin component's absorption is significantly reduced by food, necessitating a timing rule for administration one hour before or two hours after meals.

These pharmacokinetic and pharmacodynamic effects, along with explicitly documented restrictions, establish the officially recognized co-administration rules found in regulatory labeling.

Mechanism of Action

Irreversible Blockade of Cell Wall Construction

Panac's mechanism relies on two active components targeting bacterial proliferation. Both Ampicillin and Dicloxacillin act as irreversible inhibitors by binding covalently to the bacterial enzymes known as Penicillin-Binding Proteins (PBPs) located in the periplasmic space. This interaction immediately halts the final transpeptidation step of the peptidoglycan synthesis pathway essential for forming the rigid bacterial cell wall. The resulting cascade prevents structural assembly, leading to the activation of bacterial autolytic enzymes and rapid physical rupture of the microbe—a bactericidal physiological effect.

Protection from Bacterial Enzymatic Defense

The Dicloxacillin component provides crucial mechanistic synergy by being highly resistant to inactivation by the bacterial beta-Lactamase enzyme. This structural resistance preserves the functional integrity of the beta-Lactam core, allowing the primary PBP-inhibitory mechanism to fully proceed against susceptible bacteria that actively deploy this enzymatic defense system. This countermeasure enables the sustained bactericidal destruction of susceptible pathogens.

Mechanism Constraint: Dependence on Cell Division

The mechanistic function is fundamentally constrained by the bacterial life cycle. Since the block occurs during the assembly of new cell wall components, the drug's activity is dependent on the target pathogens being actively growing and dividing.

Dosage and Administration Information

How to Use Panac: Official Administration Guidelines

Panac, a fixed-dose combination of Ampicillin and Dicloxacillin, is primarily administered via the oral route as a capsule or tablet, with parenteral (Intravenous or Intramuscular) administration reserved for the constituent penicillins in severe cases. The standard dosing regimen requires administration four times daily, with doses scheduled every 6 hours to maintain consistent therapeutic drug concentrations. The dose range, which may vary from approximately 125 mg to 500 mg of the Dicloxacillin component per dose, is determined by the severity of the infection being treated.


Administration Requirements

Category Official Instruction
Timing with Food Must be taken on an empty stomach: at least 1 hour before or 2 hours after meals to ensure maximum drug absorption.
Physical Intake Swallow the capsule or tablet whole with a full glass of water. Patients should remain in an upright position for a brief period after intake.
Course Duration Treatment must be continued for a specified minimum duration, typically 7 to 10 days, and completed entirely to prevent the development of drug resistance. Longer courses, up to 21 days, are sometimes prescribed for complex infections.

Population-Specific Use

Pediatric patients receive a weight-based dosage regimen, which is divided into four equal doses throughout the day. For patients with renal impairment, dose modification may be necessary for the combination product, particularly due to the clearance of the Ampicillin component, although the Dicloxacillin component is generally stable. In cases of severe hepatic impairment, the frequency of administration may require reduction.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Panac

Panac is a fixed-dose combination antibiotic containing Ampicillin and Dicloxacillin. Official research on this specific combination was studied for use in infections caused by susceptible bacterial pathogens, particularly where resistance to standard penicillin was observed in some studies. The body of evidence includes older clinical trials, observational data, and studies related to its individual components.

Evidence for Use in Skin and Soft-Tissue Infections

Research examining this combination for skin and soft-tissue infections involved several retrospective analyses, observational studies, and small clinical trials. These studies were evaluated in adults and children with acute or disruptive episodes of infection. The outcomes that researchers monitored included measures of localized inflammatory or irritative states and overall patient-reported outcomes describing perceived discomfort. Findings describe patterns observed in the studies related to timeframes observed during the study and the appearance of local signs. However, the overall evidence is limited by factors such as modest sample sizes.

Limitations and Research Gaps

Across the research base for Panac, follow-up durations were limited, focusing heavily on outcomes measured during or immediately after the short, acute treatment interval (e.g., 7 to 14 days). Long-term outcomes, such as the persistence of changes observed in the studies or the rate of infection recurrence months or years later, are not fully established.

Evidence quality varies across studies, and many of the key trials are older, meaning they may not fully reflect contemporary standards of care or current bacterial resistance profiles. Furthermore, there is limited high-quality, modern comparative evidence to clearly determine how the fixed combination compares to using the component antibiotics separately or standard alternatives. Findings describe group patterns, not personal predictions, and the available data help contextualize what has been observed so far—and what is still uncertain.

Key Studies & References

  1. Dicloxacillin: LiverTox - Clinical and Research Information on Drug-Induced Liver Injury (NIH)
  2. Ampicillin/Cloxacillin: Review of fixed dose combinations for use in clinical practice - PubMed

Frequently Asked Questions (FAQ)

Common questions about Panac (FAQ)

Q: What is the main difference between Panac and generic pain relievers?

Panac is classified as an antibiotic and anti-infective agent. According to official product information, its sole purpose is the elimination of susceptible bacterial pathogens. This differs from pain relievers, which belong to a separate pharmacological class and are used to manage symptoms like discomfort or inflammation.


Q: Is Panac prescribed for a long time, or is it only for short-term use?

Official administration guidelines state that treatment with Panac is designed for a specified, limited duration. The course is typically completed within a minimum duration of 7 to 10 days, and in some cases up to 21 days, to clear the infection. It is not intended for continuous, long-term use.


Q: What should I do if I think I'm experiencing a Panac interaction?

Regulatory guidance is non-directive. Any concerns about potential drug interactions, side effects, or changes in a person's condition warrant consultation with a healthcare professional for appropriate evaluation.


Q: Can Panac affect my mood or cause anxiety?

Official adverse reaction lists include the broader category of Nervous System Disorders as a possible effect. Although rare, effects associated with the penicillin class, as documented in regulatory information, have included changes like confusional state or mental depression.


Q: Does Panac have a generic version available?

Panac is the brand name given to the fixed-dose combination of its two active ingredients: Ampicillin and Dicloxacillin. Both of these active components are generally available as generic medications. The generic name refers to the combination of the two ingredients.


Q: Does taking Panac with food change how well it works?

Yes, official administration rules emphasize taking Panac on an empty stomach. Regulatory documents state that taking the medicine with food is officially associated with a reduction in the Dicloxacillin component's absorption, which may lead to reduced efficacy.


Q: What is the likelihood of Panac causing dizziness?

Dizziness is not typically listed as a common side effect of Panac. However, official labeling documents the possibility of broader Nervous System Disorders, which may encompass effects like confusion or neurotoxicity. Patients experiencing any unusual neurological symptoms should seek evaluation.


Q: Can Panac be taken with common multivitamins?

Official regulatory labeling does not list a specific contraindication or interaction between Panac and common multivitamins. However, due to the complexity of supplement ingredients, official guidance recommends always discussing all concurrent supplements and products with a healthcare professional.


Q: How long does it usually take for Panac to start working?

The onset of the drug's activity is related to its absorption. Official pharmacokinetic data indicates that the active components typically reach their highest concentrations in the bloodstream approximately one to two hours following oral administration.


Q: Does Panac cause drowsiness, or can I drive while taking it?

Drowsiness is not listed as a common effect in regulatory documents. However, official information notes the possibility of rare neurological effects such as lethargy or convulsion. Any person who experiences these or any other nervous system effects while taking Panac should use caution when driving or operating machinery.


Q: Is it possible to become dependent on Panac after long-term use?

Panac is a prescription-only medicine. Regulatory information indicates that this antibiotic is not a controlled substance, and no risk of dependence or addiction is described in official documentation.


Q: Is there a different name for Panac that I might see?

Panac is the brand name for the fixed combination of Ampicillin and Dicloxacillin. You may see the names of its two generic active ingredients listed separately. The Ampicillin component has also been sold under different brand names, such as Principen or Omnipen.


Q: Why do some doctors prescribe Panac over other options?

The official purpose of the combination product is to provide enhanced effectiveness against certain bacterial strains. This is due to the Dicloxacillin component being structurally resistant to the bacterial beta-Lactamase enzyme, which can inactivate other penicillins.


Q: Is it normal to feel a bit nauseous after starting Panac?

Yes, official regulatory documents state that nausea and other gastrointestinal disturbances (such as diarrhea and vomiting) are classified as Common Effects associated with this medication. These effects are expected patterns of experience noted in official safety information.


Q: Does Panac affect birth control pills?

Yes, regulatory documents classify hormonal contraceptives as an efficacy-reducing interaction with Panac. This effect is attributed to the Dicloxacillin component, which can increase the metabolism of the hormonal agents, potentially reducing their effectiveness.


Q: What happens if I stop taking Panac suddenly?

Official guidance emphasizes that the full, prescribed course of Panac must be completed entirely. This is essential to ensure the complete elimination of the bacterial infection and to prevent the development of antibiotic drug resistance.


Q: Can Panac interact with supplements like fish oil or melatonin?

Official regulatory documents do not list a specific interaction with common supplements like fish oil or melatonin. However, due to potential complexities, official guidance recommends discussing all co-administered supplements with a healthcare professional before starting Panac.


Q: Is Panac considered a controlled substance?

No. Panac is classified as a prescription-only antibiotic. Regulatory information confirms it is not listed in the Schedules of the U.S. Controlled Substances Act or equivalent international controlled substance categories.


Q: If Panac stops working, what should I expect from my doctor?

If a patient’s symptoms do not improve during the course of treatment, regulatory practice supports a follow-up reevaluation to investigate causes, such as a non-susceptible organism, which may lead to alternative treatment options.


Q: Are there special considerations for Panac use in women versus men?

Official regulatory documents provide specific considerations for women concerning use during pregnancy, lactation, and interactions with hormonal contraceptives. Beyond these factors, general sex differences in typical dosage or efficacy are not routinely highlighted in official labeling.


Q: Why is Panac given in different dosage strengths?

Panac is provided in various dosage strengths because the official dose range is determined by the severity of the specific bacterial infection being treated. The prescribing physician selects the appropriate strength based on the clinical assessment, consistent with official prescribing information.


Q: Are there any warning signs I should look for before starting Panac?

Official warnings require a pre-treatment assessment for certain factors. This includes a thorough check for any prior history of allergy to penicillins or cephalosporins, and the exclusion of conditions such as infectious mononucleosis before treatment begins.


Q: Can Panac be taken if I have diabetes?

Official labeling does not describe diabetes as a contraindication to Panac use. However, regulatory warnings note that the Ampicillin component may cause a false positive result on certain tests for glucose in the urine, such as the Clinitest.


Q: What should I know about Panac and sun exposure?

Official adverse event reporting has documented rare cases of photoinduced skin reactions associated with the Dicloxacillin component. While this is not a common side effect, patients should be aware of the possibility of these rare dermatological reactions.

How should Panac be stored and disposed of?

Panac (Ampicillin/Dicloxacillin) must be stored and disposed of based strictly on regulatory requirements to maintain its stability and ensure safety.

Storage Conditions

Requirement Official Instruction
Temperature Store at controlled room temperature (20 C to 25 C or 68 F to 77 F), with excursions permitted up to 30 C (86 F).
Protection Keep the capsules in a tightly closed container to protect them from moisture and away from excess heat.
Child Safety Keep this and all medications out of the reach of children and pets.

Disposal Instructions

Unused or expired Panac should not be flushed down the toilet. The preferred method of disposal is through a drug take-back program or mail-back envelope. If these options are unavailable, the medication may be discarded in household trash after being mixed with an undesirable substance (like dirt or coffee grounds) and placed in a sealed container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Panac found in:

A-Z Index: